New drug targets Hard-to-Treat cancers in early trial

NCT ID NCT04617314

Completed Disease control Sponsor: RemeGen Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tested a new drug called RC108-ADC in 67 people with advanced solid tumors that have a specific protein (c-Met). The drug is designed to deliver a toxin directly to cancer cells. The main goals were to check safety and find the best dose. Researchers also looked at whether tumors shrank or growth slowed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RC108-ADC (an antibody-drug conjugate targeting c-Met protein)
What this could lead to: If successful, this could lead to a new treatment option for people with advanced solid tumors that have a specific protein called c-Met.
What could go wrong: This is an early Phase 1 trial with only 67 participants, so it is primarily testing safety. The drug may not shrink tumors or improve survival, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Hunan Cancer Hospital

Changsha, Hunan, China
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College

Beijing, Beijing Municipality, 100021, China
The First Hospital of Jilin University

Changchun, Jilin, China
Zhejiang Cancer Hospital

Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.